hope has often been more hype than realization. The story of Marfan syndrome and mutations in the FBN1 gene illustrates that identifying a mutation is only the first step in understanding the molecular pathophysiology of the disorder and that the pathway to treatment may be both complex and full of insights into unexpected areas of biology (24, 25) . Perhaps in a short time we may see the use of TGF-β blockade in preference to β-(adrenergic) blockade as a more effective treatment of many aspects of Marfan syndrome -and treatment is the ultimate goal of understanding this complex phenotype. 5 On closer inspection, however, the extent of lipodystrophy among patients with mutant PPARG similarly seems insufficient to account fully for the severity of insulin resistance. In this regard, it is instructive to compare FPLD3 with another autosomal dominant form of partial lipodystrophy, namely FPLD2 (OMIM 151660), which results from mutations in LMNA encoding nuclear lamin A/C (6). Like patients with FPLD3, FPLD2 patients have site-specific adipose tissue loss, followed by insulin resistance with hypertension and dyslipidemia, which become even worse as patients age and develop T2DM (12) . However, analysis of metabolic subphenotypes indicated that fat loss was more extensive among patients with mutant LMNA (FPLD2) than those with mutant PPARG (FPLD3) (13) . In contrast, insulin resistance and hypertension were more severe among patients with FPLD3 than those with FPLD2 (13). Thus, insulin resistance and hypertension in FPLD3 seemed to be disproportionate to the extent of lipodystrophy compared with FPLD2, which would be consistent with additional independent effects of mutant PPARG (6, 13) . The findings in the Pparg P465L/+ mice further weaken the case for direct links among adipose redistribution, insulin resistance, and hypertension (Table  1) . Could the mutation itself directly mediate hypertension?
PPARγ modulates the reninangiotensin system Tsai et al. (7) show that the PPARG mutation independently affects other pathways, in particular the renin-angiotensin system (RAS). Both human PPARG P467L heterozygotes and Pparg P465L/+ mice are hypertensive, despite the fact that the mice are minimally insulin resistant. The hypertension in the Pparg P465L/+ mice is associated with increased expression of RAS components in various adipose depots, specifically angiotensinogen and the angiotensin II (ATII) receptor subtype 1 in inguinal and gonadal fat, respectively (7). This suggests that impaired adipogenesis might locally activate the RAS, with a potential paracrine role for ATII. Alternatively, mutant PPARγ might have other effects on vascular tone. In any event, the findings suggest a more direct role for PPARγ in blood pressure regulation, possibly through linkage with the RAS. Such a link could be one reason why blood pressure decreases with thiazolidinedione treatment (14) and also why hypertensive heterozygotes for the PPARG loss-of-function mutation F388L respond well to angiotensin-converting enzyme inhibitors (10) .
Thus, Tsai et al. have provided novel insights that advance our understanding of PPARγ physiology (7). In both humans and mice, heterozygous PPARγ mutations are associated with lipodystrophy, but in the mouse there is apparently an uncoupling between the adipose repartitioning and hypertension. Furthermore, the hypertension in the Pparg P465L/+ mice might be functionally linked with RAS 
